• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Small-Molecule Inhibitors of the Proteasome's Regulatory Particle.蛋白酶体调节颗粒的小分子抑制剂。
Chembiochem. 2019 Jul 15;20(14):1739-1753. doi: 10.1002/cbic.201900017. Epub 2019 May 24.
2
Identification of 4-arylidene curcumin analogues as novel proteasome inhibitors for potential anticancer agents targeting 19S regulatory particle associated deubiquitinase.鉴定4-芳叉基姜黄素类似物作为新型蛋白酶体抑制剂,作为靶向19S调节颗粒相关去泛素酶的潜在抗癌药物。
Biochem Pharmacol. 2017 Aug 1;137:29-50. doi: 10.1016/j.bcp.2017.04.032. Epub 2017 May 3.
3
The 19S proteasome activator promotes human cytomegalovirus immediate early gene expression through proteolytic and nonproteolytic mechanisms.19S蛋白酶体激活剂通过蛋白水解和非蛋白水解机制促进人巨细胞病毒立即早期基因表达。
J Virol. 2014 Oct;88(20):11782-90. doi: 10.1128/JVI.01720-14. Epub 2014 Jul 30.
4
Hsm3/S5b participates in the assembly pathway of the 19S regulatory particle of the proteasome.Hsm3/S5b参与蛋白酶体19S调节颗粒的组装途径。
Mol Cell. 2009 Feb 13;33(3):389-99. doi: 10.1016/j.molcel.2009.01.010.
5
Approaches to Evaluate the Impact of a Small-Molecule Binder to a Noncatalytic Site of the Proteasome.评估小分子配体对蛋白酶体非催化部位影响的方法。
Chembiochem. 2021 Jun 2;22(11):1961-1965. doi: 10.1002/cbic.202100023. Epub 2021 Mar 26.
6
Assembly of the 20S proteasome.20S蛋白酶体的组装
Biochim Biophys Acta. 2014 Jan;1843(1):2-12. doi: 10.1016/j.bbamcr.2013.03.008. Epub 2013 Mar 16.
7
Proteasome-associated deubiquitinases and cancer.蛋白酶体相关去泛素化酶与癌症
Cancer Metastasis Rev. 2017 Dec;36(4):635-653. doi: 10.1007/s10555-017-9697-6.
8
Proteasome deubiquitinases as novel targets for cancer therapy.蛋白酶体去泛素化酶作为癌症治疗的新靶点。
Int J Biochem Cell Biol. 2012 Nov;44(11):1729-38. doi: 10.1016/j.biocel.2012.07.011. Epub 2012 Jul 20.
9
Structure-Driven Developments of 26S Proteasome Inhibitors.结构导向的 26S 蛋白酶体抑制剂的开发。
Annu Rev Pharmacol Toxicol. 2016;56:191-209. doi: 10.1146/annurev-pharmtox-010814-124727.
10
Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition.发现用于癌症治疗的蛋白酶体去泛素化酶抑制剂:理性设计、自然和老药再定位的启示。
Future Med Chem. 2018 Sep 1;10(17):2087-2108. doi: 10.4155/fmc-2018-0091. Epub 2018 Aug 1.

引用本文的文献

1
NMR-Guided Studies to Establish the Binding Interaction between a Peptoid and Protein.核磁共振引导的研究以确定类肽与蛋白质之间的结合相互作用。
J Am Chem Soc. 2025 Jul 15. doi: 10.1021/jacs.5c04064.
2
Regulation of ubiquitin-proteasome system and its relative pathways in pancreatic adenocarcinoma.胰腺腺癌中泛素-蛋白酶体系统及其相关通路的调控
Bioimpacts. 2024 Oct 27;15:29993. doi: 10.34172/bi.29993. eCollection 2025.
3
[Research and Therapeutic Advances of 26S Proteasome Subunit 
in Non-small Cell Lung Cancer].[26S蛋白酶体亚基在非小细胞肺癌中的研究与治疗进展]
Zhongguo Fei Ai Za Zhi. 2025 May 20;28(5):363-370. doi: 10.3779/j.issn.1009-3419.2025.106.13.
4
Exploration of degrons and their ability to mediate targeted protein degradation.降解结构域及其介导靶向蛋白质降解能力的探索。
RSC Med Chem. 2025 Jan 1. doi: 10.1039/d4md00787e.
5
Synergistic induction of mitotic pyroptosis and tumor remission by inhibiting proteasome and WEE family kinases.通过抑制蛋白酶体和 WEE 家族激酶诱导有丝分裂细胞焦亡和肿瘤消退的协同作用。
Signal Transduct Target Ther. 2024 Jul 12;9(1):181. doi: 10.1038/s41392-024-01896-z.
6
Intersections of Ubiquitin-Proteosome System and Autophagy in Promoting Growth of Glioblastoma Multiforme: Challenges and Opportunities.泛素蛋白酶体系统与自噬在促进多形性胶质母细胞瘤生长中的相互作用:挑战与机遇。
Cells. 2022 Dec 15;11(24):4063. doi: 10.3390/cells11244063.
7
Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors.手性和不对称性增加候选 ADRM1/RPN13 抑制剂的效力。
PLoS One. 2021 Sep 10;16(9):e0256937. doi: 10.1371/journal.pone.0256937. eCollection 2021.
8
Ubiquitin-proteasome system and the role of its inhibitors in cancer therapy.泛素-蛋白酶体系统及其抑制剂在癌症治疗中的作用。
Open Biol. 2021 Apr;11(4):200390. doi: 10.1098/rsob.200390. Epub 2021 Apr 28.
9
Methods for the discovery of small molecules to monitor and perturb the activity of the human proteasome.小分子的发现方法,用于监测和干扰人蛋白酶体的活性。
Future Med Chem. 2021 Jan;13(2):99-116. doi: 10.4155/fmc-2020-0288. Epub 2020 Dec 4.

本文引用的文献

1
All About the Core: A Therapeutic Strategy to Prevent Protein Accumulation with Proteasome Core Particle Stimulators.关于核心:一种使用蛋白酶体核心颗粒刺激剂预防蛋白质积累的治疗策略。
ACS Pharmacol Transl Sci. 2018 Oct 18;1(2):140-142. doi: 10.1021/acsptsci.8b00042. eCollection 2018 Nov 9.
2
UBL domain of Usp14 and other proteins stimulates proteasome activities and protein degradation in cells.Usp14 和其他蛋白质的 UBL 结构域可刺激细胞内蛋白酶体的活性和蛋白质降解。
Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):E11642-E11650. doi: 10.1073/pnas.1808731115. Epub 2018 Nov 28.
3
Cryo-EM structures and dynamics of substrate-engaged human 26S proteasome.底物结合的人源 26S 蛋白酶体的冷冻电镜结构与动态。
Nature. 2019 Jan;565(7737):49-55. doi: 10.1038/s41586-018-0736-4. Epub 2018 Nov 12.
4
Computational Studies on the Inhibitor Selectivity of Human JAMM Deubiquitinylases Rpn11 and CSN5.人类JAMM去泛素化酶Rpn11和CSN5抑制剂选择性的计算研究
Front Chem. 2018 Oct 9;6:480. doi: 10.3389/fchem.2018.00480. eCollection 2018.
5
Covalent Rpn13-Binding Inhibitors for the Treatment of Ovarian Cancer.用于治疗卵巢癌的共价Rpn13结合抑制剂
ACS Omega. 2018 Sep 30;3(9):11917-11929. doi: 10.1021/acsomega.8b01479. Epub 2018 Sep 27.
6
Small molecule inhibitors reveal allosteric regulation of USP14 via steric blockade.小分子抑制剂通过空间位阻揭示 USP14 的别构调控。
Cell Res. 2018 Dec;28(12):1186-1194. doi: 10.1038/s41422-018-0091-x. Epub 2018 Sep 25.
7
Gankyrin Promotes Tumor-Suppressor Protein Degradation to Drive Hepatocyte Proliferation.Gankyrin 通过促进肿瘤抑制蛋白降解来驱动肝细胞增殖。
Cell Mol Gastroenterol Hepatol. 2018 May 24;6(3):239-255. doi: 10.1016/j.jcmgh.2018.05.007. eCollection 2018.
8
RA190, a Proteasome Subunit ADRM1 Inhibitor, Suppresses Intrahepatic Cholangiocarcinoma by Inducing NF-KB-Mediated Cell Apoptosis.RA190,一种蛋白酶体亚基ADRM1抑制剂,通过诱导NF-κB介导的细胞凋亡来抑制肝内胆管癌。
Cell Physiol Biochem. 2018;47(3):1152-1166. doi: 10.1159/000490210. Epub 2018 Jun 15.
9
A fluorescence polarization-based competition assay for measuring interactions between unlabeled ubiquitin chains and UCH37•RPN13.一种基于荧光偏振的竞争分析方法,用于测量未标记的泛素链与UCH37•RPN13之间的相互作用。
Anal Biochem. 2018 Jun 1;550:84-89. doi: 10.1016/j.ab.2018.04.018. Epub 2018 Apr 23.
10
Transcriptome-wide discovery of coding and noncoding RNA-binding proteins.转录组范围内编码和非编码 RNA 结合蛋白的发现。
Proc Natl Acad Sci U S A. 2018 Apr 24;115(17):E3879-E3887. doi: 10.1073/pnas.1718406115. Epub 2018 Apr 10.

蛋白酶体调节颗粒的小分子抑制剂。

Small-Molecule Inhibitors of the Proteasome's Regulatory Particle.

机构信息

Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, 575 West Stadium Avenue, West Lafayette, Indiana, 47907, USA.

出版信息

Chembiochem. 2019 Jul 15;20(14):1739-1753. doi: 10.1002/cbic.201900017. Epub 2019 May 24.

DOI:10.1002/cbic.201900017
PMID:30740849
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6765334/
Abstract

Cells need to synthesize and degrade proteins consistently. Maintaining a balanced level of protein in the cell requires a carefully controlled system and significant energy. Degradation of unwanted or damaged proteins into smaller peptide units can be accomplished by the proteasome. The proteasome is composed of two main subunits. The first is the core particle (20S CP), and within this core particle are three types of threonine proteases. The second is the regulatory complex (19S RP), which has a myriad of activities including recognizing proteins marked for degradation and shuttling the protein into the 20S CP to be degraded. Small-molecule inhibitors of the 20S CP have been developed and are exceptional treatments for multiple myeloma (MM). 20S CP inhibitors disrupt the protein balance, leading to cellular stress and eventually to cell death. Unfortunately, the 20S CP inhibitors currently available have dose-limiting off-target effects and resistance can be acquired rapidly. Herein, we discuss small molecules that have been discovered to interact with the 19S RP subunit or with a protein closely associated with 19S RP activity. These molecules still elicit their toxicity by preventing the proteasome from degrading proteins, but do so through different mechanisms of action.

摘要

细胞需要持续合成和降解蛋白质。为了在细胞内维持蛋白质的平衡水平,需要一个精心控制的系统和大量的能量。蛋白酶体可以将不需要的或受损的蛋白质降解成较小的肽单位。蛋白酶体由两个主要亚基组成。第一个是核心颗粒(20S CP),在这个核心颗粒内有三种类型的苏氨酸蛋白酶。第二个是调节复合物(19S RP),它具有多种活性,包括识别标记为降解的蛋白质并将其运送到 20S CP 中进行降解。已经开发出 20S CP 的小分子抑制剂,是治疗多发性骨髓瘤(MM)的特效药物。20S CP 抑制剂会破坏蛋白质平衡,导致细胞应激,最终导致细胞死亡。不幸的是,目前可用的 20S CP 抑制剂具有剂量限制的脱靶效应,并且可以迅速产生耐药性。本文讨论了一些小分子,它们被发现与 19S RP 亚基或与 19S RP 活性密切相关的蛋白质相互作用。这些分子通过阻止蛋白酶体降解蛋白质来发挥其毒性作用,但它们通过不同的作用机制来实现这一点。